Aelix Therapeutics completes Series A funding of $12.7M for therapeutic HIV vaccine

Jan-18
 

Aelix Therapeutics, a drug development company specialized in the discovery and development of immunotherapies against HIV infection, today announces that it has completed a Series A funding round of €11.5 M ($12.7 M). Ysios Capital, a Spanish investment fund, led the round.

Read More >>